Literature DB >> 12841658

A study of the clinical features and the treatment of breast cancer in 374 patients in Iran.

Morteza Salsali1, Dehghan Tazejani, Amir Javadi, Babak Mahmud, Hamid-Reza Sali, Ali Hirani, Mohamed Baghbanian, Rambod Hajipour.   

Abstract

For evaluation of clinical features and state of the art in the treatment of breast cancer in Iran, we studied 347 consecutive patients among 1123 hospital admissions (in 14 hospitals in three cities) who had undergone surgery for a mass in their breasts during a 2-year period, 1991 to 1992. Thirty-nine additional patients with breast cancer had been treated in the second year of the study, an increment of 8.9%. The relative frequency of positive biopsies for breast cancer was 31% for the entire series. In Teheran, Babol and Yazd, it was 35%, 24.2% and 18.1%, respectively. The mean age for the entire series was 48 +/- 1 years. The mean age for patients from Yazd was 51 +/- 9, which was higher than the mean age (41.5 +/- 16) of patients from Babol. The pathologic diameter was > 2.1 cm (pT2 and pT3) in 59.36% of the tumors. In 15.56% of the patients, the exact size of the tumor was not available. In 83.45% of the patients, the tumors were reported as infiltrating ductal carcinoma. Of 173 patients in whom regional nodes had been histologically examined, 80% had metastatic involvement (stage II disease). Modified radical mastectomy had been used more than radical mastectomy in this series, but the choice of the operation was not related to the size of tumor.

Entities:  

Mesh:

Year:  2003        PMID: 12841658     DOI: 10.1177/030089160308900205

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  1 in total

1.  Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients.

Authors:  Shuting Li; Xiangtang Wang; Jiao Yang; Meng Lv; Xiao Zhang; Chunli Li; Lingxiao Zhang; Yanwei Shen; Xiaoman Zhang; Zheling Chen; Fan Wang; Xin Wang; Dan Li; Min Yi; Jin Yang
Journal:  Thorac Cancer       Date:  2017-10-04       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.